Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review
Autor: | Javier De Diego-Adeliño, José Manuel Crespo, Fernando Mora, Adrián Neyra, Pedro Iborra, Luis Gutiérrez-Rojas, Selman F. Salonia |
---|---|
Rok vydání: | 2021 |
Předmět: | |
Zdroj: | Expert Opinion on Drug Safety. 21:673-690 |
ISSN: | 1744-764X 1474-0338 |
Popis: | Vortioxetine is a multimodal-acting antidepressant that provides improvements on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has been found to be one of the most effective and best tolerated options for major depressive disorder (MDD) in head-to-head trials.The present review intends to gather the most relevant and pragmatic data of vortioxetine in MDD, specially focusing on new studies that emerged between 2015 and 2020.Vortioxetine is the first antidepressant that has shown improvements both in depression and cognitive symptoms, due to the unique multimodal mechanism of action that combine the 5-HT reuptake inhibition with modulations of other key pre- and post-synaptic 5-HT receptors (agonism of 5-HT |
Databáze: | OpenAIRE |
Externí odkaz: |